Photo taken from Jayastu Senapati/X
May 21, 2024, 04:55
Jayastu Senapati: Optimal use of Azacytidine Venetoclax in AML Patients in Indian Scenario
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared a post on X:
“Looking forward to discussing the optimal use of Hypomethylating Agent (HMA) – Venetoclax in patients with Acute Myeloid Leukaemia (AML), focussing on Indian/Low and Middle-Income Country (LMIC) settings- May 17, CT 8:30AM (IST 7PM).”
Jun 16, 2024, 19:51